Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On

Henri Zenuni,Niccolò Candelise,Piergiorgio Grillo,Clara Simonetta,Roberta Bovenzi,Alberto Ferri,Cristiana Valle, Nicola Biagio Mercuri,Tommaso Schirinzi

Journal of Integrative Neuroscience（2022）

引用 0|浏览3

暂无评分

摘要

Although preliminary and limited, this study indicates that patients under different iMAO-Bs may present distinct profiles of CSF neurodegeneration-related biomarkers, probably because of the differential neurobiological effects of the drugs. Larger studies are now needed to confirm and extend these initial observations.

查看译文

关键词

CSF biomarkers,MAO inhibitors,Parkinson's disease,neurodegeneration,neuroprotection,rasagiline,safinamide,selegiline

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要